Curbside Consultation in IBD: 49 Clinical Questions, Second Edition

David T Rubin, MD; Sonia Friedman, MD; Francis A Farraye, MD MSc

Question 20: What Are The Risks Of Biologic Therapies, And How Do You Communicate Them To Patients? (continued)

L. Campbell Levy, MD; Corey A. Siegel, MD

Biologic therapies for inflammatory bowel disease (IBD) may be beneficial when other treatments have failed, minimize corticosteroid use, and temper the natural course of disease. Three anti-tumor necrosis factor (TNF) agents—infliximab, adalimumab, and certolizumab pegol—are currently available. Natalizumab, an antiadhesion molecule, has also become available. The benefits of these medications are exciting, but they may be associated with rare, serious side effects. It is critical for clinicians to understand the risks and benefits of these medications and be able to…